Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05901714 · ClinicalTrials.gov registry record · Phase 1

A Study to Assess the Effect of Phenytoin on the Drug Levels of Afimetoran and the Effect of Afimetoran on the Drug Levels of Midazolam

A Phase 1 study of Healthy Participants, sponsored by Bristol-Myers Squibb.

Completed
Registry status
Phase 1
Development phase
65
Enrollment target
1
Study location

NCT05901714: Completed Phase 1 study of Healthy Participants, sponsored by Bristol-Myers Squibb.

NCT05901714 is a Phase 1 study of Healthy Participants that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 65 participants, roughly in line with the 65-participant average among 119 other Healthy Participants trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05901714, a Phase 1 study of Healthy Participants, has completed, sponsored by Bristol-Myers Squibb.

COMPLETED
Registry status
Phase 1
Development phase
65 participants
Enrollment target
1
Study location

Study Summary

This study will consist of 2 parts. The study will evaluate whether administration of phenytoin impacts the single-dose drug levels of afimetoran and BMT-271199 (Part 1) and will evaluate whether multiple administrations of afimetoran impact the drug levels of midazolam and 1-hydroxymidazolam (Part 2).

Primary Outcome

Parts 1 and 2

Conditions Studied

Interventions

  • DRUG Midazolam
  • DRUG Afimetoran
  • DRUG Phenytoin

Study Locations (1)

Florida

  • Local Institution - 0001 - Miami

Trial Details

FieldValue
Enrollment Target 65 participants
Start Date 2023-06-14
Est. Completion 2024-04-11
Phase Phase 1
Bristol-Myers Squibb

1,025 total trials

What the finished NCT05901714 record still lists

NCT05901714 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 65 participants, a relatively small participant target, roughly in line with the 65-participant average among 119 other Healthy Participants trials with a reported enrollment target.

The record links to 1 condition, with Healthy Participants appearing as the primary indexed condition, and to 3 interventions - of which Midazolam is the first listed.

NCT05901714 reports a single indexed study location in Florida.

Frequently Asked Questions

What is clinical trial NCT05901714 about?

NCT05901714 is a clinical study titled "A Study to Assess the Effect of Phenytoin on the Drug Levels of Afimetoran and the Effect of Afimetoran on the Drug Levels of Midazolam". This study will consist of 2 parts. The study will evaluate whether administration of phenytoin impacts the single-dose drug levels of afimetoran and BMT-271199 (Part 1) and will evaluate whether multiple administrations of afimetoran impact the drug levels of midazolam and 1-hydroxymidazolam (Part ...

What is the current status of trial NCT05901714?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 65 participants. The study started on 2023-06-14. Estimated completion is 2024-04-11.

What conditions does trial NCT05901714 study?

This clinical trial studies the following conditions: Healthy Participants.

What interventions are being tested in trial NCT05901714?

The interventions under investigation include: Midazolam (DRUG), Afimetoran (DRUG), Phenytoin (DRUG).

Who is sponsoring clinical trial NCT05901714?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05901714 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy Participants

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05901714's enrollment target sits among peer trials

65 36th of 119 higher than 84 of 119 other Healthy Participants trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Healthy Participants trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03366116 · 65 participants · Phase 1

    5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors

  • NCT03603730 · 65 participants · NA

    Vagal Nerve Stimulation for Functional Dyspepsia and Gastroparesis

  • NCT03796559 · 65 participants · NA

    Magseed Enabled Long-Term Localization of Axillary Lymph Nodes

  • NCT03993106 · 65 participants · Phase 2

    A Study of sEphB4-HSA in Kaposi Sarcoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05901714, the US trial registry maintained by the National Library of Medicine. NCT05901714 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.